Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390676 · ClinicalTrials.gov registry record · Phase 1
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
A Phase 1 study of Neoplasms, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Study locations
NCT00390676: Completed Phase 1 study of Neoplasms, sponsored by Adherex Technologies.
NCT00390676 is a Phase 1 study of Neoplasms that has completed, run by Adherex Technologies. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390676, a Phase 1 study of Neoplasms, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10
- Study locations
Study Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.
Conditions Studied
Interventions
- DRUG ADH -1 and carboplatin
- DRUG ADH -1 and docetaxel
- DRUG ADH -1 and capecitabine
Study Locations (10)
Texas
- Texas Oncology, PA - Dallas
- Tyler Cancer Center - Tyler
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- Cancer Centers of Florida - Ocoee
Indiana
- Central Indiana Cancer Centers - Indianapolis
New York
- New York Oncology Hematology P.C. - Albany
Ohio
- Dayton Oncology & Hematology, P.A - Kettering
South Carolina
- Cancer Centers of the Carolinas - Greenville
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-11 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00390676 record still lists
NCT00390676 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which ADH -1 and carboplatin is the first listed.
NCT00390676 lists 10 locations in 9 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT00390676 about?
NCT00390676 is a clinical study titled "A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine". N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in...
What is the current status of trial NCT00390676?
This trial is currently completed. It is a Phase 1 study. The study started on 2006-11. Estimated completion is 2009-11.
What conditions does trial NCT00390676 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00390676?
The interventions under investigation include: ADH -1 and carboplatin (DRUG), ADH -1 and docetaxel (DRUG), ADH -1 and capecitabine (DRUG).
Who is sponsoring clinical trial NCT00390676?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390676 being conducted?
This trial has 10 study locations across Colorado, Florida, Indiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia